Chondrogenic Potential and Homogeneity of Cell Populations of Donor and Recipient Cells in a Fresh Osteochondral Allograft

Abstract

Fresh osteochondral allografts have been widely used to treat cartilage lesions for more than 100 years1. Transplantation of cartilage and bone in the form of an allograft allows osseous healing while maintaining the articular cartilage architecture. This composite tissue transplant remains intact in vivo for extensive periods of time with a favorable mechanical and biological environment. The chondrocytes of the graft are thought to actively remodel the extracellular matrix environment, and thus contribute to the tissue integrity. We recently reported that allograft cells could survive up to twenty-nine years after transplantation without the need for systemic immunosuppression2. Although mosaic cell populations have been demonstrated in other forms of transplantation, these have always been under the umbrella of long-term systemic immunosuppression3,4. In a classic study, Langer and Gross5 showed that intact articular cartilage surfaces obtained by removing the subchondral bone of rat femoral heads and filling of the osseous segments with acrylic cement exhibited essentially no humoral immune response in contrast to that seen with minced cartilage or isolated chondrocyte transplants. This finding has been attributed to the so-called “immunoprivileged” status of articular cartilage, which protects the chondrocytes from the immune system of the host. The extent to which allograft chondrocytes retain their gene expression profiles and chondrogenic capacities remains unknown. Our goal was to compare gene expression, proliferation rate, and chondrogenic potential between host and allograft chondrocytes isolated three years after an unsuccessful fresh osteochondral allograft transplant in the knee. The patient was informed that data concerning her case would be submitted for publication, and she provided consent. The study was performed in full compliance with our institutional review board (IRB). Our IRB at University of California Davis Medical Center does not consider case reports to be research and does not …